CORT ALERT: Class Action After FDA Rejection & Patent Loss!

Company Overview

Corcept Therapeutics (NASDAQ: CORT) is a commercial-stage pharmaceutical company focused on drugs that modulate the hormone cortisol. Its flagship product Korlym (mifepristone) was approved in 2012 as the first treatment for Cushing’s syndrome (hypercortisolism) (www.sec.gov). Korlym is a cortisol receptor antagonist indicated for patients with endogenous Cushing’s who have type 2 diabetes or hyperglycemia and are not candidates for surgery. The company has built a pipeline of next-generation selective cortisol modulators, notably relacorilant, designed to treat serious conditions (endocrine disorders, cancers, etc.) with fewer side effects than Korlym (www.sec.gov) (www.sec.gov). As of early 2026, Corcept remains heavily reliant on Korlym for revenue, while advancing relacorilant and other candidates through clinical trials.

Dividend Policy & Shareholder Returns

Corcept has never paid a dividend on its common stock and does not plan to pay cash dividends for the foreseeable future (www.sec.gov) (www.sec.gov). Instead, management has favored share repurchases as a way to return capital to shareholders. In 2023, the company spent about $154.5 million buying back its own shares (including a tender offer in April 2023) (ir.corcept.com). This aggressive buyback activity continued into 2025 – for example, Corcept repurchased $115.4 million of stock in just the second quarter of 2025 (ir.corcept.com). The substantial repurchases (totaling roughly $246 million in 2025) were funded by the company’s growing cash flows and have reduced the share count. Bottom line: Corcept’s shareholder return policy has prioritized buybacks over dividends, effectively resulting in a 0% dividend yield while aiming to boost earnings per share and support the stock price.

Financial Position and Leverage

Profitability: Thanks to Korlym’s commercial success in the niche Cushing’s syndrome market, Corcept has been consistently profitable. Full-year 2024 net income was $141.2 million, a 33% increase from 2023’s $106.1 million (ir.corcept.com). This translates to diluted earnings of roughly $1.36 per share for 2024 (up from $0.94 in 2023), reflecting strong operational leverage as revenues grew.

Revenue Growth: Corcept reported 2024 revenue of $675.0 million, up 40% year-over-year (ir.corcept.com). This robust growth was driven by increased diagnosis and treatment of hypercortisolism – the company noted record numbers of new patients and prescribers as physicians more actively screen for Cushing’s syndrome (ir.corcept.com). Despite looming generic competition (discussed below), Korlym sales continued to climb in 2024, even straining the capacity of Corcept’s specialty pharmacy distribution network by mid-2025 (ir.corcept.com). Management initially issued 2025 revenue guidance of $900–$950 million, anticipating continued expansion (ir.corcept.com). However, they later trimmed 2025 guidance to $850–$900 million as supply chain limitations constrained near-term sales growth (ir.corcept.com). (It’s important to note this guidance was given before the late-2025 FDA setback.)

Balance Sheet & Debt: Corcept entered 2025 with a strong liquidity position and essentially no debt. Cash and marketable investments stood at $603.2 million as of December 31, 2024 (ir.corcept.com) (ir.corcept.com), providing a substantial cushion. The company has not reported any significant long-term debt in recent SEC filings, and ongoing operations have been financed through internally generated cash and equity. This conservative balance sheet means low leverage and no near-term maturities to worry about. In fact, Corcept earns interest income on its cash, rather than paying interest, which bolsters net income slightly. With over half a billion dollars in cash, the company has flexibility to fund R&D, potential litigation costs, or strategic investments even after its heavy share buybacks.

Coverage Ratios: Given the lack of debt, traditional interest coverage ratios are a non-issue (there is minimal or no interest expense). Instead, one could view cash flow coverage of R&D and other expenses. Corcept’s operating cash flow from its profitable Korlym sales has comfortably covered its research spending so far. For instance, in 2024 the company’s net income ($141M) and significant depreciation/tax credits yielded strong cash generation, enabling over $170M net increase in cash after buybacks (ir.corcept.com). The ample cash reserves and ongoing profits suggest that Corcept can cover its fixed obligations (like operating leases and R&D commitments) many times over. Overall, the financial position is solid – a cash-rich, debt-free balance sheet that provides resilience amid upcoming challenges.

Valuation and Market Performance

Prior to the recent setbacks, Corcept’s stock had been a strong performer, reflecting optimistic expectations for its pipeline. Shares rallied through 2024 and into 2025, more than doubling from their early-2024 lows. By late 2025, CORT traded above $70 per share, implying a market capitalization around $7 billion (roughly 10× 2024 sales and over 50× earnings). This rich valuation was premised on continued Korlym growth and the successful FDA approval of relacorilant. However, the events at the end of 2025 dramatically altered the outlook and the stock’s value:

– FDA Rejection Impact: On December 31, 2025, Corcept shocked investors by disclosing an FDA Complete Response Letter (CRL) for relacorilant’s New Drug Application. The FDA refused to approve relacorilant for Cushing’s syndrome at this time, despite Phase 3 trials meeting primary endpoints (www.biospace.com) (www.fiercebiotech.com). This news halved the stock price overnight – from $70.20 on Dec 30 to $34.80 on Dec 31 (www.prnewswire.com) (www.fiercebiotech.com). In a single trading day, over $35 per share in value (50% of market cap) was wiped out. By early 2026, CORT shares were trading in the mid-$30s, down ~50% from their 2025 peak.

– Post-crash Valuation: At ~$35/share, Corcept’s market cap is about $3.5 billion, which is ~5× trailing 2024 revenue and around 25× 2024 earnings. This multiple may still not be “cheap” given the looming erosion of Korlym’s monopoly (and thus potential earnings decline). Investors are now pricing in a much more uncertain growth trajectory. If Korlym sales hold up better than feared and relacorilant eventually gains approval, the valuation could prove reasonable. But with new competitive headwinds (generics) and a delayed pipeline, the forward P/E is murky – earnings in 2026–2027 are expected to drop before any new product ramps up. In short, the stock’s collapse has reset expectations: Corcept went from a high-growth premium valuation to a more discounted pricing, reflecting its higher risk profile.

– Peer/Comp Comparison: There are few direct comparables to Corcept (a profitable orphan drug company with an endocrine focus). However, other biotech firms with a single major product and a pipeline setback often trade at low single-digit revenue multiples if the product’s longevity is in question. For instance, Corcept’s Price/Sales (~5×) is now closer to the biotech industry average for commercial-stage companies, whereas the ~10× it boasted pre-rejection was at a growth stock premium. Another peer consideration: Xeris Biopharma (XERS), which markets a competing Cushing’s drug Recorlev, saw its stock move in sympathy with Corcept’s news. Xeris shares fell ~6% on Feb 19, 2026, when Corcept’s patent appeal loss was announced (news.bloomberglaw.com), reflecting how Corcept’s challenges are shifting focus to competitors.

Overall, Corcept’s valuation has dramatically compressed after the FDA and patent blows. The stock now trades more like a challenged pharmaceutical play than a high-growth story. Investors are likely to remain cautious until there is clarity on how fast Korlym revenues decline and if/when relacorilant (or other pipeline drugs) can fill the gap.

Recent Developments & Catalysts

Patent Loss to Teva (Generic Competition)

A major overhang for Corcept has been the battle to protect Korlym from generic competition. Corcept’s composition-of-matter patent for mifepristone expired in 2016, and its orphan drug exclusivity for Korlym ended in 2019 (www.sec.gov). The company has since relied on method-of-use patents (expiring 2028–2038) to fend off generics (www.sec.gov). In 2018, Teva Pharmaceuticals filed an ANDA to market a generic Korlym, prompting Corcept to sue for patent infringement. This culminated in a December 29, 2023 court ruling firmly in Teva’s favor: the U.S. District Court found that Teva’s proposed generic would not infringe Corcept’s patents (www.sec.gov) (news.bloomberglaw.com). The decision essentially cleared the legal path for Teva’s generic mifepristone 300mg tablets.

– Market Reaction: The patent defeat caught investors by surprise and eliminated hope of extending Korlym’s monopoly. Corcept’s stock plunged ~38% in after-hours trading on Dec 29, 2023 (news.bloomberglaw.com). By the next trading session, shares were down to ~$24 (from ~$32), reflecting the market pricing in eventual erosion of Korlym’s high-margin sales (apnews.com).

– Generic Launch: With a green light from the court, Teva announced it would launch its generic Korlym. (Teva’s ANDA had actually been FDA-approved back in 2020, pending patent resolution (www.sec.gov).) Teva’s generic officially hit the market in early 2024, introducing direct competition. However, initial impact was muted – Jefferies analysts noted that Teva lacked the specialized distribution network to immediately capture Korlym’s niche patient population (news.bloomberglaw.com). Korlym is dispensed through specialty pharmacies and requires careful patient management, giving the incumbent a distribution advantage. As a result, Corcept continued to post revenue growth through 2024, suggesting the generic’s uptake was slow or limited.

– Ongoing Litigation: Corcept appealed the district court’s decision, but in February 2026 the U.S. Court of Appeals (Fed. Circuit) upheld the ruling against Corcept (www.sec.gov) (news.bloomberglaw.com). The appeals court confirmed that Teva did not infringe the two Korlym patents in question, ending Corcept’s last chance to block Teva via current patents. Corcept’s stock fell again (~28%) on the appeal loss, hitting its lowest levels since 2024 (news.bloomberglaw.com). With the patent fight effectively over, multiple generics (Teva, and potentially others like Sun and Hikma) are now free to enter the market. Corcept had previously settled with other generic filers (e.g. Hikma Pharmaceuticals in 2022) on terms that likely allowed them to launch following Teva (ir.corcept.com) (www.sec.gov). This means Korlym sales will face increasing generic competition going forward, likely at significantly lower prices. The company itself acknowledges that a successful generic launch “may materially harm our results of operations and financial condition” (www.sec.gov).

Implications: The patent loss is a critical turning point. Korlym accounted for essentially all of Corcept’s revenue, so generics threaten that cash cow. Corcept may respond by increasing patient support programs, leveraging its specialty pharmacy relationships, or even lowering price to retain market share. But over time, one should expect Korlym’s revenue to peak and then decline as generics gain traction. This puts added pressure on Corcept’s pipeline (especially relacorilant) to deliver new revenue streams. It’s worth noting Corcept is also facing an antitrust lawsuit from Teva (filed in 2018, ongoing as of 2025) alleging Corcept used illegal tactics to delay generic competition (www.law360.com). That case underscores the contentious fight over Korlym’s monopoly and could pose financial liability if Corcept is found to have violated antitrust laws. In sum, the “patent loss” to Teva introduces substantial long-term risk to Corcept’s core business and was a precursor to the stock’s volatility.

FDA Rejection of Relacorilant (CRL in Dec 2025)

While grappling with patent challenges, Corcept was also racing to bring its next big product to market. The company’s lead pipeline candidate relacorilant is a selective cortisol modulator developed to treat endogenous Cushing’s syndrome (hypercortisolism) without Korlym’s drawbacks. Corcept conducted two key trials: the GRACE trial, a Phase 3 in patients with Cushing’s and hypertension, and GRADIENT, a supportive trial in patients with adrenal adenomas. These trials met their endpoints and formed the basis of a New Drug Application submitted to the FDA in 2025 (www.biospace.com) (www.fiercebiotech.com). Given the positive data and relacorilant’s orphan drug status, Corcept’s management frequently expressed optimism about approval. In fact, during 2024 earnings calls and presentations, executives indicated a “high likelihood” of FDA approval for relacorilant – framing the trial results as “powerful support” for the NDA (www.globenewswire.com). Investors shared this optimism, helping propel CORT’s share price upward through 2025 in anticipation of a new revenue stream.

However, in a stunning turn of events, the FDA issued a Complete Response Letter (CRL) on December 31, 2025, declining to approve relacorilant for Cushing’s syndrome (www.yahoo.com). According to Corcept’s disclosure, the FDA acknowledged that the Phase 3 GRACE study met its primary endpoint and that GRADIENT provided confirmatory evidence (www.fiercebiotech.com). Nevertheless, regulators concluded they “could not arrive at a favorable benefit-risk assessment for relacorilant” without additional evidence of effectiveness (www.biospace.com) (www.fiercebiotech.com). In plain terms, the agency was not convinced that relacorilant’s efficacy (in lowering cortisol-related morbidities) was strong enough to justify approval at that time. The exact concerns were not fully detailed publicly, but subsequent reporting suggests the FDA had signaled doubts earlier: FierceBiotech revealed that the FDA had warned Corcept in pre-NDA meetings about “significant review issues” and concerns about the relacorilant clinical program (www.fiercebiotech.com). In fact, the FDA explicitly cautioned Corcept that success was unlikely – advising the company “to expect significant review issues if you were to submit your application.” (www.fiercebiotech.com) Despite these red flags, Corcept pressed forward with the NDA, only to be “surprised and disappointed” by the rejection, in the words of CEO Dr. Joseph Belanoff (www.biospace.com).

– Market Reaction: The FDA rejection was a severe blow to Corcept’s prospects. Relacorilant was widely seen as the future growth driver (and a necessary replacement for Korlym once generics arrived). The CRL news, coming immediately after the Christmas holiday, triggered a massive selloff. Corcept’s share price collapsed ~50% in one day, falling from $70.20 to $34.80 on Dec 31, 2025 (www.prnewswire.com) (www.fiercebiotech.com). This single event destroyed over $3 billion in shareholder value. It also prompted several securities litigation firms to announce investigations, as the stock drop implied that prior company statements might have been overly rosy or misleading (more on the class action below).

– FDA’s Rationale: Although Corcept did not initially elaborate beyond the need for “additional evidence of effectiveness,” analysts and industry experts speculated on the reasons. One possibility is that the magnitude of relacorilant’s benefit in Cushing’s syndrome was not convincing enough. If the trials met endpoints but only showed modest improvements, the FDA may have felt the drug’s risk/benefit wasn’t clearly favorable – especially given that effective surgical options and other medical therapies exist for Cushing’s. It’s also notable that the FDA was concerned about liver safety with relacorilant, according to reports by STAT and others (www.statnews.com). (Elevated liver enzymes were a potential issue observed in earlier trials, raising caution). However, the CRL language focused on efficacy, suggesting the agency might want a longer or additional trial to confirm that lowering cortisol via relacorilant translates into tangible clinical benefit for patients.

– Corcept’s Response: Corcept’s management expressed shock at the outcome but reiterated commitment to the program. Dr. Belanoff stated, “I am confident we will find a way to get relacorilant to the patients it could help. We will meet with the FDA as soon as possible to discuss the best path forward.” (www.biospace.com) (www.fiercebiotech.com). In practice, the “path forward” likely means figuring out what extra data the FDA needs – possibly an entirely new Phase 3 trial or an extension of existing studies. This will entail additional time and expense; relacorilant’s approval for Cushing’s is now delayed by years (if it can be salvaged at all).

– Pipeline Impact: The CRL doesn’t just affect the Cushing’s indication. Corcept has been developing relacorilant for other uses too – notably a form of ovarian cancer. In September 2025, the FDA accepted a separate NDA for relacorilant in platinum-resistant ovarian cancer, granting a PDUFA decision date of July 11, 2026 (ir.corcept.com) (www.biospace.com). That application is based on a different trial (RELENT study) which reportedly showed relacorilant plus chemotherapy improved median survival to 16.0 months vs 11.9 months with chemo alone (www.fiercebiotech.com). It remains to be seen if the FDA’s concerns in Cushing’s will spill over to oncology. The efficacy bar and risk tolerance in cancer are different (patients have a high unmet need), so some analysts believe the ovarian cancer review could still succeed on its own merits (www.fiercebiotech.com). Nonetheless, the Cushing’s CRL may make regulators scrutinize relacorilant’s data package more skeptically across the board. Apart from relacorilant, Corcept’s pipeline includes candidates like dazucorilant (for ALS) and cortisol modulators for NASH, but those are in earlier stages. In sum, the FDA rejection of relacorilant’s lead indication leaves Corcept’s pipeline in a state of uncertainty – the one near-term product launch that was expected to materialize has evaporated for now.

Shareholder Class Action & Legal Scrutiny

In the wake of the FDA rejection and the stock’s plunge, Corcept now faces legal fallout from investors. Specifically, at least two securities class action lawsuits have been filed (and multiple law firms seeking lead plaintiffs) alleging that Corcept and its executives misled investors about relacorilant’s approval prospects. The class period cited in these suits is October 31, 2024 through December 30, 2025 (www.prnewswire.com) (www.globenewswire.com), which corresponds to the time during which the company was publicly upbeat about relacorilant, up to the day before the CRL announcement.

The allegations center on claims that Corcept failed to disclose material information and made overly optimistic statements regarding relacorilant. For example, one complaint (Allegheny County Employees’ Retirement System v. Corcept) asserts that management represented relacorilant had a “high likelihood” of FDA approval, even as the FDA had repeatedly warned Corcept of serious concerns (www.prnewswire.com) (www.fiercebiotech.com). The suit notes that the truth emerged on Dec 31, 2025, when Corcept revealed the CRL and the stock fell 50% (www.prnewswire.com). According to the lawsuit, this dramatic decline (from $70.20 to $34.80 in one day) caused investors significant losses (www.prnewswire.com). The class action is suing under federal securities laws, accusing Corcept of making false or misleading statements (or omissions) about the relacorilant NDA, thereby inflating the stock price. In essence, plaintiffs argue they were blindsided by the FDA rejection because the company painted an unjustifiably positive picture of relacorilant’s approval chances.

Law firms such as Kahn Swick & Foti (KSF) and Gainey McKenna & Egleston have put out alerts to shareholders regarding these claims (www.prnewswire.com) (www.globenewswire.com). For instance, KSF’s February 27, 2026 press release emphasizes the 50% stock drop and reminds investors of an April 2026 deadline to seek lead plaintiff status (www.prnewswire.com). It specifically cites Corcept’s December 2025 disclosure that the FDA could not find a favorable benefit-risk profile for relacorilant (www.prnewswire.com). Gainey McKenna’s announcement similarly highlights that Corcept touted the relacorilant trial results as “powerful support” for the NDA, creating an impression of likely approval (www.globenewswire.com). These cases will proceed in Northern District of California and may take years to resolve.

Investor Implications: The class action reflects red flags about corporate transparency. If it is proven that Corcept knowingly downplayed the FDA’s concerns (as suggested by FierceBiotech’s reporting of explicit FDA warnings (www.fiercebiotech.com)), that would indicate a serious communication failure or misconduct. At a minimum, the suit means Corcept will have to devote resources to a legal defense or settlement. Such litigation can also distract management and potentially unearth internal documents, so it’s a situation investors will monitor closely. It’s worth noting that the SEC has penalized biotech executives in the past for misrepresenting FDA feedback (www.fiercebiotech.com), underscoring the seriousness of the allegations. Corcept, for its part, has not publicly commented on the lawsuit yet (www.fiercebiotech.com). The outcome is uncertain – many shareholder suits get settled out of court if some evidence of over-optimism is found, whereas a strong defense could argue that the company believed in its data in good faith.

Beyond the class action, Corcept’s legal challenges include the aforementioned antitrust case with Teva (www.law360.com) and any liabilities from generic settlements. These legal issues collectively create an overhang that could weigh on the stock. Investors often apply a higher risk discount to companies entangled in litigation, especially if there’s a possibility of financial damages or corporate governance concerns. For now, the class action serves as a cautionary tale – it highlights potential red flags in how Corcept’s management communicated risk, and it will keep the company under the microscope of both regulators and the plaintiff’s bar.

Key Risks and Red Flags

Corcept’s investment narrative has clearly shifted, and there are several key risks and red flags for investors to consider going forward:

– Generic Erosion of Korlym: The number one risk is the loss of Korlym exclusivity. With Teva’s generic now approved and patent appeals exhausted, Korlym’s days of monopoly profits are likely numbered. Even if uptake was slow initially, generics inevitably drive prices down. Korlym had been Corcept’s cash engine (over $600M/year run-rate in 2024 (ir.corcept.com)), so any significant cut to its market share or pricing will hit revenues and margins hard. Additional generic entrants (Hikma, Sun, etc.) could come to market, intensifying competition. Red flag: Corcept’s own 10-K warns that Teva’s launch “may materially harm our results”, indicating how critical this threat is (www.sec.gov). The company could see its core revenue peak in 2025 and start declining thereafter, absent new products.

– Regulatory/Pipeline Uncertainty: The FDA’s rejection of relacorilant raises uncertainty about the pipeline. Corcept must determine why the FDA was unconvinced and whether it can remedy this (through new trials or data analysis). There’s a risk that relacorilant could be tied up for years or possibly never approved for Cushing’s if the additional evidence is hard to generate. Moreover, there’s no guarantee the FDA will approve relacorilant’s ovarian cancer indication in 2026 – negative sentiment might bleed over, or efficacy there might face scrutiny. Other pipeline programs (like in AML, ALS, NASH) are early-stage and far from commercialization. Red flag: Without relacorilant, Corcept currently has no second act ready to replace Korlym’s revenues once generics bite.

– Overreliance on One Product: Even before generics, Corcept is essentially a one-product company, with all sales from Korlym (in one indication). This concentration risk means any single event – e.g. a safety issue, new competing therapy, or payer change – could dramatically affect sales. There are already competing Cushing’s drugs (Signifor, Isturisa, Recorlev) (www.sec.gov) (www.sec.gov), though so far Korlym held its own. Still, reliance on one product is a classic red flag for biotech companies, amplified now by the product’s patent expiry status.

– Capital Allocation Questions: Corcept pursued very large share buybacks, even as its stock soared and despite knowing the company faced binary risks (FDA approval, patent outcomes). In 2025 alone it spent nearly $246 million on repurchases, some likely at $50–60+ per share prices (ir.corcept.com). With hindsight, one might question if that capital would have been better saved to weather the storm or invested in pipeline development or acquisitions. If Korlym’s cash flows decline, those repurchases (essentially cash out the door) could constrain future flexibility. Open question: Was management too focused on boosting short-term share value? The buybacks could be seen as a confidence signal at the time, but in light of the stock’s crash, they now look like a poor use of capital (paying high prices for stock that collapsed).

– Management Credibility: The developments around relacorilant have put a spotlight on Corcept’s management and their communication. The fact that the FDA explicitly warned of issues, yet executives professed surprise at the CRL (www.fiercebiotech.com), suggests either internal misjudgment or intentional Pollyannaish messaging. The pending class action will dissect what was said vs. what was known. Red flag: If it turns out management ignored FDA feedback or wasn’t fully transparent with investors, trust will be eroded. Biotech investing often hinges on management’s credibility in navigating regulatory affairs; Corcept’s leadership now has to rebuild that credibility with both the FDA and investors.

– Legal and Liability Risks: The shareholder lawsuit introduces the risk of financial or reputational damage. While securities class actions often settle for insurance money, a protracted case could air dirty laundry (e.g. emails with FDA). Separately, the antitrust lawsuit by Teva (alleging Corcept tried to block generics unfairly) could result in damages or a settlement cost (www.law360.com). The company might also face royalty or settlement obligations from past deals (for instance, Corcept licenses or pays royalties on Korlym’s use of mifepristone, though specifics are not highlighted here). All told, legal issues could potentially cost tens of millions, which is manageable given cash on hand, but it’s still a risk factor.

– Market Volatility: Investors should expect continued stock volatility. Corcept’s share price will be very sensitive to any news on the FDA front or generic competition developments. Positive surprises (e.g. FDA willingness to review relacorilant on existing data, or slower-than-expected Korlym erosion) could spark relief rallies. Negative surprises (another trial required, faster generic uptake, etc.) could lead to further drops. With a mid-cap valuation and a binary-event-driven story, CORT will likely trade with high volatility in the near term.

Open Questions & Outlook

Looking ahead, Corcept faces several open questions that will determine its long-term trajectory:

– Can Korlym Sales Be Sustained (or Softened in Decline)? Korlym’s growth trend until 2024 was impressive, but generics change the game. A key question is how quickly will generic mifepristone erode Korlym’s sales? Will Corcept be able to retain a portion of the market through patient support, brand loyalty, or a second-generation formulation? Notably, the specialty distribution model may slow generic penetration initially (news.bloomberglaw.com), but insurers and hospitals will eventually favor a cheaper generic for most patients. Corcept may consider strategies like price matching generics or developing a new formulation (perhaps an extended-release?). The trajectory of Korlym revenue over the next 1-2 years is critical: a slower decline would give Corcept more breathing room; a sharp decline would squeeze finances (though they have cash reserves to buffer somewhat).

– What’s Next for Relacorilant in Cushing’s? Corcept needs to clarify the plan to address the FDA’s concerns. Will they run another Phase 3 trial? If so, that could take several years (enrolling enough Cushing’s patients is challenging) and cost a substantial sum. Or can they gather additional “real-world” evidence or expand an ongoing study to satisfy the FDA? Perhaps a subset analysis or a higher dosage could show stronger efficacy, but these are speculative. The timing of any resubmission is unknown – investors will want an update from the FDA meeting (which Corcept aimed to have as soon as possible (www.biospace.com)). If the FDA signals a clear path (like “do X trial and we’ll reconsider”), that could restore some hope. If the path is unclear or the required studies are too onerous, Corcept might even decide to halt further development in this indication – a worst-case outcome that would write off a lot of invested R&D.

– Will Relacorilant Succeed in Oncology? A big near-term catalyst is the July 2026 FDA decision for relacorilant in platinum-resistant ovarian cancer (www.fiercebiotech.com). This is an entirely separate indication with separate data. Analysts will be watching if the FDA convenes an advisory committee or issues any signals. A key question: Could the ovarian NDA be approved despite the Cushing’s CRL? It’s possible, since the risk-benefit calculation in oncology is different. If approved, relacorilant could launch in oncology (perhaps in 2027 after labeling and manufacturing prep) – a smaller market than Cushing’s, but still meaningful. It would validate Corcept’s technology in at least one domain. On the flip side, if the FDA also rejects or delays the ovarian indication, it would suggest broader skepticism about relacorilant, which would be a bad sign. So this is a pivotal upcoming event – success would give Corcept a much-needed win and a new product to commercialize (with possible off-label use in other cancers), whereas failure would deepen the pipeline woes.

– How Will Corcept Deploy Its Cash? With over $500 million in cash post-2025 (ir.corcept.com), Corcept has a war chest. Now that buybacks might slow (the stock is cheaper but the company also must conserve cash for uncertain times), what will they do with the cash? Open questions include: Could Corcept pursue an acquisition or licensing deal to diversify its portfolio? The company might look for another late-stage or commercial asset to reduce reliance on Korlym’s lineage. Alternatively, they may invest heavily in R&D to advance their own pipeline (e.g. accelerate trials for dazucorilant in ALS, or their selective cortisol modulators in depression or liver disease). Investors will be evaluating if Corcept’s capital allocation shifts to a more defensive posture (saving cash for a rainy day) or an aggressive one (making a bold acquisition). How wisely the company uses its significant cash will influence its ability to navigate the crisis. It’s also possible that the cash could dwindle if Korlym revenues drop and the company keeps high R&D spending – so burn rate management is an open question.

– Outcome of Legal Matters? The resolution of the shareholder class action is an open question. Will Corcept settle, and for how much? Many such cases result in settlements without admission of wrongdoing, often paid by D&O insurance. If a settlement occurs, the amount might be modest relative to Corcept’s cash (maybe on the order of tens of millions). However, if evidence emerges of intentional misrepresentation, that could lead to deeper consequences (SEC investigations or management changes). Similarly, the Teva antitrust case outcome is pending – could Corcept be on the hook for damages to Teva or an injunction? While these legal questions may take backseat to operational ones, they will eventually need answers and could impact financials or management credibility.

– Management and Governance Changes? Often after major setbacks, companies see leadership changes. One might ask: Will Corcept’s board make changes at the top? Dr. Belanoff (CEO) has led the company for over two decades; he also co-founded Corcept. If investors lose confidence, there might be pressure to bring in new leadership experienced in regulatory negotiations or to split the CEO and Chairman roles for accountability. So far, there’s no indication of such changes, but it remains an open question if the board and management will adjust strategy or personnel in response to the recent failures. Additionally, will Corcept’s investor relations approach change? Perhaps more cautious guidance or tempered expectations in the future to rebuild credibility.

In conclusion, Corcept Therapeutics is at a critical juncture. The patent loss and FDA rejection have created a perfect storm challenging both its current revenue and future pipeline. The company’s strong balance sheet and past profitability give it a fighting chance to weather the storm, but execution in the next 1-2 years is key. Investors should watch for updates on relacorilant’s path forward, Korlym sales trends under generic pressure, and how management steers the company (both strategically and financially) through this turbulent period. The risk profile has undoubtedly risen, but so have the potential rewards if Corcept can overcome these setbacks. As of now, the story hinges on resolving uncertainties – a class action lawsuit in the background, crucial FDA discussions ahead, and the challenge of pivoting from a one-drug success to a diversified, resilient business. The coming quarters will provide more answers to these open questions and determine whether Corcept can regain its footing or continue to stumble.

Sources:

– Corcept Therapeutics 10-K and Investor Relations – company business overview and risk disclosures (www.sec.gov) (www.sec.gov), dividend policy (www.sec.gov), share repurchases (ir.corcept.com), and financial results (ir.corcept.com) (ir.corcept.com). – Bloomberg Law / AP News – reporting on patent litigation outcome (Corcept vs. Teva) and immediate stock reaction (news.bloomberglaw.com) (apnews.com). – Corcept press release (Business Wire) – announcement of FDA Complete Response Letter for relacorilant, including FDA’s stated rationale (www.biospace.com) (www.fiercebiotech.com) and CEO’s response (www.biospace.com). – FierceBiotech / Reuters – analysis of FDA decision and industry context, noting 50% stock plunge and prior FDA warnings to the company (www.fiercebiotech.com) (www.fiercebiotech.com). – Court documents & Corcept IR – details on generic Korlym competition and patent appeal status (Fed Circuit Feb 2026) (www.sec.gov) (news.bloomberglaw.com); Jefferies analyst commentary on distribution challenges for Teva’s generic (news.bloomberglaw.com). – Law firm releases (KSF, Gainey McKenna) – description of securities class action allegations and class period, highlighting alleged misrepresentations about relacorilant’s approval likelihood (www.prnewswire.com) (www.globenewswire.com). – Bloomberg Law – note on antitrust suit by Teva alleging Corcept’s tactics to delay generics (www.law360.com).

These sources provide a factual basis for the events and figures discussed, ensuring the analysis above is grounded in verified information.

For informational purposes only; not investment advice.